Delyon J et al.
STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network
Journal of Investigative Dermatology 2018 138(1)
doi: 10.1016/j.jid.2017.07.839
![Logo France Génomique](https://www.france-genomique.org/wp-content/uploads/2019/03/logo-FG-blue-RVB-medium.png)
Delyon J et al.
STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network
Journal of Investigative Dermatology 2018 138(1)
doi: 10.1016/j.jid.2017.07.839